Vanguard Group Inc. raised its position in shares of Cantel Medical Corp. (NYSE:CMN) by 3.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 2,762,913 shares of the company’s stock after buying an additional 84,162 shares during the period. Vanguard Group Inc. owned approximately 6.68% of Cantel Medical Corp. worth $189,894,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Henderson Group PLC boosted its stake in Cantel Medical Corp. by 51.1% in the second quarter. Henderson Group PLC now owns 680,016 shares of the company’s stock worth $46,737,000 after buying an additional 230,084 shares during the last quarter. Neuberger Berman Group LLC increased its position in Cantel Medical Corp. by 23.1% in the second quarter. Neuberger Berman Group LLC now owns 952,754 shares of the company’s stock valued at $65,483,000 after buying an additional 179,096 shares during the last quarter. Kalmar Investments Inc. DE increased its position in Cantel Medical Corp. by 68.4% in the second quarter. Kalmar Investments Inc. DE now owns 285,232 shares of the company’s stock valued at $19,604,000 after buying an additional 115,832 shares during the last quarter. Advisors Asset Management Inc. purchased a new position in Cantel Medical Corp. during the second quarter valued at $6,672,000. Finally, Congress Asset Management Co. MA purchased a new position in Cantel Medical Corp. during the second quarter valued at $4,608,000. Institutional investors and hedge funds own 81.61% of the company’s stock.
Cantel Medical Corp. (NYSE:CMN) opened at 75.90 on Tuesday. Cantel Medical Corp. has a 52-week low of $55.01 and a 52-week high of $81.63. The stock has a market cap of $3.14 billion, a P/E ratio of 52.78 and a beta of 1.59. The firm’s 50-day moving average price is $77.95 and its 200 day moving average price is $71.30.
Cantel Medical Corp. (NYSE:CMN) last issued its earnings results on Thursday, September 29th. The company reported $0.48 EPS for the quarter, beating the Zacks’ consensus estimate of $0.37 by $0.11. Cantel Medical Corp. had a return on equity of 16.70% and a net margin of 9.02%. The company earned $179 million during the quarter. During the same quarter in the previous year, the firm earned $0.39 earnings per share. The business’s revenue was up 18.3% on a year-over-year basis. Equities analysts predict that Cantel Medical Corp. will post $1.98 earnings per share for the current year.
The firm also recently disclosed a semiannual dividend, which will be paid on Tuesday, January 31st. Stockholders of record on Tuesday, January 17th will be given a dividend of $0.07 per share. The ex-dividend date is Thursday, January 12th. This is an increase from Cantel Medical Corp.’s previous semiannual dividend of $0.06. This represents a dividend yield of 0.18%. Cantel Medical Corp.’s payout ratio is currently 8.33%.
Several equities analysts recently weighed in on the company. Benchmark Co. set a $83.00 price objective on Cantel Medical Corp. and gave the company a “buy” rating in a research note on Saturday, October 1st. Needham & Company LLC began coverage on Cantel Medical Corp. in a research note on Wednesday, August 24th. They issued a “hold” rating for the company.
In other news, CAO Steven C. Anaya sold 5,500 shares of the business’s stock in a transaction that occurred on Monday, October 10th. The stock was sold at an average price of $77.07, for a total transaction of $423,885.00. Following the completion of the transaction, the chief accounting officer now directly owns 48,132 shares in the company, valued at $3,709,533.24. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ann E. Berman sold 1,453 shares of the business’s stock in a transaction that occurred on Friday, September 30th. The stock was sold at an average price of $77.56, for a total value of $112,694.68. Following the transaction, the director now owns 5,424 shares of the company’s stock, valued at $420,685.44. The disclosure for this sale can be found here. Insiders own 15.30% of the company’s stock.
About Cantel Medical Corp.
Cantel Medical Corp. is a provider of infection prevention and control products and services in the healthcare market. The Company’s segments include Endoscopy, Water Purification and Filtration, Healthcare Disposables, Dialysis and Specialty Packaging. Its Endoscopy segment includes medical device reprocessing systems, disinfectants, detergents and other supplies.
Receive News & Ratings for Cantel Medical Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cantel Medical Corp. and related companies with MarketBeat.com's FREE daily email newsletter.